A comprehensive mini-review published today after peer review in Brain Medicine by Dr. Tao Ma and colleagues at Wake Forest ...

Nimbus Therapeutics announced it has entered into a multi-year research collaboration and $1.3 exclusive license agreement ...

Lilly has seen dramatic sales growth over the last couple of years from its injectable, dual GLP-1/GIP agonist obesity ...

Credit: Shutterstock. PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. The Food and Drug Administration (FDA) has granted Fast Track ...

Nephrodi Therapeutics Inc. has entered an agreement with The McQuade Center for Strategic Research and Development LLC (MSRD), a member of the Otsuka family of pharmaceutical companies, to collaborate ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a clinical-stage company that is working to design and develop breakthrough medicines through its powerful computational drug discovery engine, ...

PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH. The Phase 2a ...

A study published in the journal Cell Reports describes a new pathway related to the activity of receptors that are associated with several metabolic or cardiovascular diseases such as diabetes, ...